Boehringer Ingelheim Pharmaceuticals

Texas Attorney General Ken Paxton and his counterparts from 49 other states and the District of Columbia announced a $13.5 million settlement Dec. 21 with Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) over alleged off-label marketing and deceptive claims about four of its prescription drugs: Micardis®, Aggrenox®, Atrovent®, and Combivent®.